Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed To Accrual

Canadian Cancer Trials Group IND. 197 - Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer - was closed to accrual on August 2, 2013. A total of 47 patients were accrued to the study, of which 37 were evaluable for response.

Thanks to participating centres, investigators and staff, and patients for supporting this trial.